Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 2/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
| ▸ | CPA3 | P15088 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855726 | 1.00 | POLB (0.46) | POLBLMNAKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL4856801 | 1.00 | POLB (0.46) | POLBLMNAKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL4883931 | 0.87 | POLB (0.45) | POLBKMT2AALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL4883935 | 0.87 | POLB (0.45) | POLBKMT2AALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL4884968 | 0.87 | POLB (0.45) | POLBKMT2AALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL4882850 | 0.85 | DPP7 (0.52) | LMNAKMT2AALDH1A1GAAMEN1 | |
| SCHEMBL8996549 | 0.85 | KMT2A (0.44) | POLBLMNAKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL8996651 | 0.85 | KMT2A (0.44) | POLBLMNAKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL14034567 | 0.85 | TDP1 (0.53) | POLBLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL4855282 | 0.85 | KMT2A (0.44) | POLBLMNAKMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008791-A1 | CHEMICAL COMPOUNDS | BORAH INC (US) | 2026-01-08 | — | — | US | disclosed |
| CN-114341145-B | Chemical compound | 博拉公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-114341145-A | Chemical compound | 博拉公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-1493819-B1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | UBE INDUSTRIES (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2318377-B1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2318377-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-7449325-B2 | Process for enzymatically producing either optically active N-substituted β-amino acids or esters thereof or optically active N-substituted 2-homopipecolic acids or esters thereof | UBE INDUSTRIES, LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | UBE INDUSTRIES, LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1493819-A1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | Ube Industries, Ltd. (JP) | 2005-01-05 | — | — | EP | disclosed |
| EP-0690862-B1 | QUINOLONE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | KOREA RES INST CHEM TECH (KR) | 2002-07-10 | — | — | EP | disclosed |
| US-5770597-A | ANTIBIOTIC | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1998-06-23 | — | — | US | disclosed |
| EP-0690862-A1 | NOVEL QUINOLONE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994015938-A1 | NOVEL QUINOLONE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1994-07-21 | — | — | WO | disclosed |
| US-4785003-A | N-disubstituted glycine and B-amino-propionic acid derivatives having anti-ulcer activity | BIOMEASURE, INC. (US) | 1988-11-15 | — | — | US | disclosed |
| US-4598067-A | Antiulcer compounds | BIOMEASURE, INC. (US) | 1986-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008791-A1 | CHEMICAL COMPOUNDS | JAK3, JAK2, JAK1 | POLB 1709/4885LMNA 4610/4885KMT2A 1919/4885 |
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | CYP8B1, SRR, HM13 | POLB 2773/4885LMNA 1936/4885KMT2A 4504/4885 |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | POLB 316/4885LMNA 3554/4885KMT2A 4093/4885 |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | POLB 316/4885LMNA 3554/4885KMT2A 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.